Investor Relations

Rigel's Mission

Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases.

Grifols begins commercializing TAVLESSE® in France, Italy and Spain to treat chronic immune thrombocytopenia

View Press Release View All

Sep 2, 2021 • 7:30am EDT

Rigel to Participate in Three Upcoming Investor Conferences

Sep 1, 2021 • 7:30am EDT

Data from NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients Published in Clinical Infectious Diseases

Aug 13, 2021 • 7:30am EDT

Rigel Pharmaceuticals Provides Update on COVID-19 Program

September 2021

View Presentation

Cantor Fitzgerald Global Healthcare Conference

View Event View All

Q2 2021

Quarter Ended Jun 30, 2021

Earnings Release

PDF HTML

Audio

Earnings Webcast

Earnings Presentation

PDF

10-Q

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2020

Investor Contact Information

Company

Rigel Pharmaceuticals, Inc.
1180 Veterans Blvd
South San Francisco, CA 94080